Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City |
| |
Authors: | Pedro Torres-González Juanita Romero-Díaz Miguel Enrique Cervera-Hernández Mario Ocampo-Torres Luis Gerardo Chaires-Garza Ernesto Alejandro Lastiri-González Yemil Atisha-Fregoso Miriam Bobadilla-del-Valle Alfredo Ponce-de-León José Sifuentes-Osornio |
| |
Affiliation: | 1.Department of Infectious Diseases,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Mexico City,Mexico;2.Department of Immunology and Rheumatology,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Mexico City,Mexico;3.Department of Medicine,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Mexico City,Mexico |
| |
Abstract: | To determine, among systemic lupus erythematosus patients, factors associated with active tuberculosis. We performed a case-control study, in a tertiary-care center in Mexico City. We defined cases as systemic lupus erythematosus patients with active tuberculosis and matched them 1:1 with systemic lupus erythematosus patients without tuberculosis (controls) by age, date of systemic lupus erythematosus diagnosis, and disease duration. We analyzed clinical variables, lupus disease activity (SLEDAI-2K), and accumulated damage (SLICC/ARC-DI). We performed a nonconditional logistic regression to determine factors associated with tuberculosis. We identified 72 tuberculosis cases among systemic lupus erythematosus patients, 58% were culture confirmed. Thirty-three percent (24/72) were pulmonary only, 47.2% (34/72) extrapulmonary only, and 19.4% both. After adjustment for age, gender, and socioeconomic status, SLEDAI-2K and SLICC/ARC-DI, a 1-year cumulative dose of prednisone ≥?3 g (odds ratios (OR), 18.85; 95% confidence interval (95% CI), 6.91–51.45) was associated with tuberculosis, and the antimalarial treatment was protective (OR, 0.13; 95% CI, 0.04–0.36). Among systemic lupus erythematosus patients, cumulative dose of prednisone is associated with tuberculosis. Further research is required to elucidate the protective effect of antimalarial drugs for tuberculosis. Preventive strategies must be implemented in patients at risk. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|